Exam (elaborations)
NAPSRX CHAPTER 11 (CLINICAL TRIAL) QUESTIONS AND ANSWERS WITH SOLUTIONS 2024
NAPSRX CHAPTER 11 (CLINICAL TRIAL) QUESTIONS AND ANSWERS WITH SOLUTIONS 2024
[Show more]
Preview 4 out of 39 pages
Uploaded on
September 17, 2024
Number of pages
39
Written in
2024/2025
Type
Exam (elaborations)
Contains
Questions & answers
Institution
Napsrx
Course
Napsrx
$15.49
Also available in package deal from $96.24
100% satisfaction guarantee
Immediately available after payment
Both online and in PDF
No strings attached
Also available in package deal (1)
$ 238.13
$ 96.24
17 items
1. Exam (elaborations) - Napsrx exam questions and answers with solutions 2024
2. Exam (elaborations) - Napsrx cnpr exam (revised 18th edition) questions and answers with solutions 2024
3. Exam (elaborations) - Napsr/cnpr exam questions and answers with solutions 2024
4. Exam (elaborations) - Napsr exam (practice quizzes) and answers with solutions 2024
5. Exam (elaborations) - Napsrx study guide questions and answers with solutions 2024
6. Exam (elaborations) - Napsrx final exam question and answers with solutions 2024
7. Exam (elaborations) - Cnpr exam word doc questions and answers with solutions 2024
8. Exam (elaborations) - Napsr quiz 16 questions and answers with solutions 2024
9. Exam (elaborations) - Napsr quiz 14 questions and answers with solutions 2024
10. Exam (elaborations) - Napsr certification questions and answers with solutions 2024
11. Exam (elaborations) - Napsrx chapter 8 questions and answers with solutions 2024
12. Exam (elaborations) - Napsr 16th edition review questions and answers with solutions 2024
13. Exam (elaborations) - Napsr 1-3 questions and answers with solutions 2024
14. Exam (elaborations) - Napsr cnpr chapter 12 biopharmaceutical drug development questions and answers with s...
15. Exam (elaborations) - Napsrx ch. 21 terminology questions and answers with solutions 2024
16. Exam (elaborations) - Napsrx chapter 11 (clinical trial) questions and answers with solutions 2024
17. Exam (elaborations) - Chapter 5 & 6 questions and answers with solutions 2024
Show more
NAPSRX CHAPTER 11 (CLINICAL TRIAL)
QUESTIONS AND ANSWERS WITH
SOLUTIONS 2024
ClinicalFTrialF-
FANSWERFAFstudyFofFhumanFsubjectsFthatFisFintendedFtoFascertainFanFinvestigationalFproduct'sFsafetyFandF
efficacyFbyFanalyzingFits...
-clinical
-pharmacologicalFand/orFotherFpharmacodynamicFeffects
-absorption
-distribution
-metabolism
-excretion
-adverseFreactions
EthicalFConsiderationsF-FANSWERF1.)FSocialFValue
2.)FScientificFValidity
3.)FFairFSubjectFSelection
4.)FInformedFConsent
5.)FFavorableFRisk-BenefitFRatio
6.)FIndependentFReviewFBoard/IndependentFEthicsFCommitteeF(IRB/IEB)
7.)FRespectFforFHumanFSubjects
,SocialFValueF-
FANSWERFClinicalFtrialFisFjustifiedFbasedFonFscientificFresearch,FandFwillFresultFinFimprovementsFinFhealthFor
FadvancementFofFscientificFknowledge
-FThisFrequirementFhelpsFensureFresourcesFareFnotFdirectedFatFnon-
meaningfulFclinicalFresearchFandFthatFhumanFsubjectsFareFnotFexploited
ScientificFValidityF-
FANSWERFtheFclinicalFtrialFshouldFbeFconductedFmethodicallyFwithFclearFobjectivesFandFoutcomesFthatFareF
statisticallyFverifiable
-
theFpreclinicalFandFtoxicologicalFdataFshouldFhaveFbeenFcarefullyFanalyzedFandFshouldFconfirmFtheFscientifi
cFfinding
-theFtrialFshouldFnotFbeFbiased,FandFshouldFbeFexecutedFwithoutFunreasonableFcaveatsFandFconditions
FairFSubjectFSelectionF-
FANSWERFsubjectsFshouldFbeFselectedFbasedFonFscientificFobjectivesFandFnotFonFwhetherFtheFsubjectFisFpri
vilegedForFvulnerable,ForFbecauseFofFconvenience
-inclusionFandFexclusionFcriteriaFareFwellFthoughtFoutFandFdesignedFtoFsatisfyFtheFscientificFdataF
-mustFbeFdocumentedFevidenceFtoFsupportFtheFchoiceFofFselectionFcriteria
InformedFConsentF-
FANSWERFsubjectsFshouldFbeFinformedFaboutFtheFaims,Fmethods,Frisks,FandFbenefitsFofFtheFtrial
-theFavailableFalternativesFshouldFbeFexplained
-subjectsFshouldFnotFbeFpressuredFtoFenrollingFinFtrial,FandFshouldFbeFallowedFtoFleave
-forFyoungFandFincapacitatedFpeople,FproxyFdecisionFfromFtheirFrepresentativesFmustFbeFobtained
FavorableFRisk-BenefitFRatioF-
FANSWERFwhetherFpossibleFclinicalFtrialFsubjectsFshouldFbeFsubjectedFtoFminimalFriskFandFmaximalFbenefit
,-shouldFbeFbasedFonFprovenFscientificFdataFgatheredFfromFpre-clinicalFstage
-shouldFnotFbeFconductedFifFthereFisFanyFdoubtFaboutFtheFrisk-benefitFration
IndependentFReviewFBoard/IndependentFEthicsFCommitteeF(IRB/IEC)F-
FANSWERFinsuresFthatFtheFindependentFpartyFassessesFtheFclinicalFtrialFtoFaddressFtheFquestionFofFconflictFi
nterests
-
actsFasFaFthirdFpartyFtoFoverseeFwelfareFofFtheFtrialFsubjectsFandFensureFtrialFisFconductedFinFaccordanceFtoF
theFstudy
-hasFaFrightFtoFstopFtrialForFrequireFproceduresFandFmethodsFbeFchanged
-members:Fclinicians,Fscientists,Flawyers,FreligiousFpeople,FandFlayFpeople
RespectFforFHumanFSubjectsF-
FANSWERFsubjectsFshouldFbeFprotected,FtheirFprogressFinFtheFtrialFmonitoredFcloselyFandFprovidedFwithFap
propriateFtreatment
-
newFdevelopmentsFinFtheFtrialFmushFbeFrelayedFtoFsubjectsFwithoutFprejudice,FandFsubjectsFdecisionsFsho
uldFbeFhonored
-outcomesFmustFbeFcommunicatedFtoFtheFsubjectsFpromptlyFandFinFanFunbiasedFway
PhaseF1F-FANSWERFtheFfirstFexperimentFinFwhichFaFdrugFisFtestedFonFtheFhumanFbody
-primaryFaimFisFtoFassessFtheFsafetyFofFtheFnewFdrug,Fpharmacokinetics,FandFpharmocodynamics
-10-100FhealthyFvolunteersFrecruited
-dosesFincreasedFasFtrialFprogresses,FmonitoredFcloselyFtoFcheckFtheirFtoleranceFandFsideFeffects
-samplesFtakenFtoFevaluateFabsorption,Fdistribution,Fmetabolism,FandFevaluation
-observationsFonFhowFtheyFfeel,FvitalFsigns,FandFbehavioralFmatters
PhaseF2F-FANSWERFexaminesFtheFsafetyFandFeffectivenessFofFtheFdrugFinFaFtargetedFdiseaseFgroup
-50-500Fpeople,F1-2Fyears
-hasFaFcontrolFgroup,FrandomizedFandFblindedFtoFsubjects
, -helpsFdetermineFeffectiveFdoseFandFtheFdosingFregimenFofFfrequencyFandFduration
-specificFclinicalFendpointsForFmarkersF(definitiveF&Fsurrogate)FassessFinteractionFofFdrugFandFdisease
-
statisticalFanalysisFconductedFtoFevaluateFtheFinfluenceFofFtheFdrugFonFdifferentFpatientFgroupsFandFdeter
mineFoptimumFconditions
PhaseF3F-FANSWERFconfirmsFtheFefficacyFofFtheFdrugFinFaFmushFlargerFpatientFgroup
-severalFhundredFtoFtensFofFthousandsFofFpeople,F2-5Fyears
-multi-siteFtrial:FconductedFinFseveralFlocations
-pivotalFtrial:FitsFresultsFdetermineFtheFeffectivenessFofFtheFdrug
-theseFresultsFhelpFsetFdrug'sFdosage,FtreatmentFfrequency,Fduration,FandFtargetFpatientFgroup
-resultsFsubmittedFtoFregulatoryFauthoritiesFtoFseeFapprovalFtoFmarketFtheFdrug
PhaseF4F-FANSWERFpost-
marketingFapprovalFtrialsFtoFmonitorFefficacyFandFsideFeffectsFofFtheFdrugFinFanFuncontrolledFreal-
lifeFsituationF
-collectFinformationFtoFobserveFdrugsFefficacy,FsideFeffects,FpatientsFqualityFofFlife,FandFcost-effectiveness
InvestigatorF-FANSWERFTheFpersonFwhoFconductsFtheFtrial
-FIfFthereFisFaFteam,FthenFthereFisFaFPrincipalFInvestigator
-
FResponsibilityFisFtoFensureFthatFGCPFisFbeingFimplementedFinFtheFcourseFofFtheFtrial,FthatFtheFsubject'sFrigh
tsFandFwelfareFareFrespected,FthatFtheFstudy'sFtransparencyFisFmaintained,FandFthatFthereFareFnoFconflictsF
ofFinterest
-
FShouldFbeFableFtoFmaintainFimpartiality,FmeaningFthatFtheyFshouldFbeFneitherFemployedFbyFtheFSponsor,Fn
orFotherwiseFexpectedFtoFbenefitFfinanciallyFfromFtheFdrug'sFsuccess